DOCSLIB.ORG

Training Manual

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Training Manual TRAINING MANUAL CONTENTS CONTENTS PART I: ALLERGY GENERAL CONCEPTS 1. INTRODUCTION TO ALLERGY .................................................................................. 3 1.1 Definition .................................................................................................................... 3 1.2 History ....................................................................................................................... 3 1.3 Epidemiology .............................................................................................................. 4 2. ANATOMY OF THE RESPIRATORY SYSTEM ............................................................ 6 2.1 Upper respiratory tract .............................................................................................. 6 2.2 Nose and paranasal sinuses ...................................................................................... 7 2.3 Pharynx ...................................................................................................................... 7 2.4 Larynx ........................................................................................................................ 8 2.5 Ear .............................................................................................................................. 8 3. ANATOMY OF THE SKIN AND FUNCTIONS .................................................................. 9 3.1 Introduction ................................................................................................................ 9 3.2 Skin structure and functions ..................................................................................... 9 3.2.1 Epidermis ............................................................................................................ 10 3.2.2 Dermis ................................................................................................................. 10 3.2.3 Hypodermis ......................................................................................................... 11 3.2.4 Skin adnexa ........................................................................................................ 11 3.2.5 Sensory receptors in the skin ............................................................................. 11 3.2.6 Blood distribution in the skin .............................................................................. 11 3.2.7 Biological functions of the skin .......................................................................... 11 4. SKIN LESIONS AND INFLAMMATION ...................................................................... 13 4.1 Introduction ................................................................................................................ 13 4.2 Inflammatory process in the skin .............................................................................. 13 4.2.1 Vascular mechanisms of skin inflammation ....................................................... 13 4.2.2 Cellular mechanisms of skin inflammation ......................................................... 13 4.2.3 Lesion repair ....................................................................................................... 14 4.3 Skin lesions ................................................................................................................ 15 4.3.1 Primary lesions ................................................................................................... 15 4.3.2 Secondary lesions ............................................................................................... 16 5. THE IMMUNE SYSTEM ............................................................................................ 20 5.1 Non-specific immunity ............................................................................................... 20 5.2 Specific immunity ...................................................................................................... 20 5.2.1 Humoral immunity ............................................................................................... 21 5.2.2 Cell mediated (cellular) immunity ...................................................................... 21 5.2.3 Primary and secondary immune response .......................................................... 22 6. THE HYPERSENSITIVITY REACTION (ALLERGY) ..................................................... 24 6.1 Types of allergic reactions ......................................................................................... 24 6.1.1 Early allergic reaction ......................................................................................... 24 6.1.2 Late allergic reaction (allergic inflammation) .................................................... 25 7. ALLERGIC RHINITIS ................................................................................................. 27 7.1 Traditional classification ........................................................................................... 27 7.2 ARIA classification ..................................................................................................... 29 7.3 Allergic rhinitis and quality of life.............................................................................. 30 7.4 Allergic rhinitis diagnosis........................................................................................... 32 7.4.1 Clinical history and physical examination .......................................................... 32 7.4.2 Physical examination .......................................................................................... 33 For internal use only CONTENTS 7.4.3 Allergy tests ....................................................................................................... 33 7.5 Treatment of allergic rhinitis...................................................................................... 34 7.5.1 Allergen avoidance.............................................................................................. 34 7.5.2 Immunotherapy ................................................................................................... 35 7.5.3 Drug therapy ....................................................................................................... 35 7.5.3.1 First-generation antihistamines .................................................................. 36 7.5.3.2 Second-generation antihistamines ............................................................. 37 7.5.3.3 Adverse reactions of antihistamines .......................................................... 40 8. URTICARIA .............................................................................................................. 42 8.1 EAACI/GA2LEN/EDF/WAO definition ........................................................................ 42 8.2 EAACI/GA2LEN/EDF /WAO classification ............................................................... 43 8.2.1 Acute urticaria .................................................................................................... 43 8.2.2 Chronic urticaria ................................................................................................. 43 8.3 Treatment of urticaria ................................................................................................ 45 8.3.1 Identification and elimination/avoidance of the stimulus ................................. 45 8.3.2 Symptomatic pharmacological treatment .......................................................... 45 8.3.3 Treatment of urticaria according to EAACI/GA2LEN/EDF/WAO guidelines ...... 45 9. OTHER ALLERGIC SKIN CONDITIONS – INSECT BITE PRURIGO ............................. 47 PART II: PRODUCT PROFILE 1. PHARMACOLOGICAL PROPERTIES OF RUPATADINE .............................................. 53 1.1 Chemical structure .................................................................................................... 53 1.2 Pharmacodynamics .................................................................................................... 53 1.2.1 Mode of action .................................................................................................... 54 1.2.2 Antihistamine activity ......................................................................................... 54 1.2.3 Anti-PAF activity ................................................................................................. 58 1.2.4 Anti-inflammatory and antiallergic activity ........................................................ 63 1.2.5 Anticholinergic effects ....................................................................................... 65 2. RUPATADINE PHARMACOKINETIC PROPERTIES .................................................... 66 2.1 Absorption and distribution ........................................................................................ 67 2.2 Metabolism and excretion ......................................................................................... 67 2.3 Pharmacokinetics in children .................................................................................... 67 2.4 Elderly population ..................................................................................................... 68 3. RUPATADINE EFFICACY PROFILE IN ALLERGIC RHINITIS .......................................... 70 3.1 Seasonal allergic rhinitis (SAR) ................................................................................. 71 3.1.1 Dose-finding studies ..........................................................................................
Load more

Recommended publications
  • Puritis in Cats
    Clinical Approach to the Pruritic Cat Dr Robert Hilton BVSc(Hons) MACVSc CertVD MRCVS When dealing with cats with skin disease, it is important to understand that cats are not small dogs. The same cause may elicit different reaction patterns in different cats. Cats were worshipped as gods in ancient Egypt, and have not quite got over the fact. They are often difficult to pill, resent bathing, fail to eat elimination diets, hunt and steal food and love to remove topical medication by licking as soon as it is put on. The principal causes of feline pruritus are listed below: Common Allergies and ectoparasites − Flea bite allergy − Food allergy (and on rare occasions, non immune-mediated adverse food ) reactions − Atopic dermatitis − Mosquito hypersensitivity − Reactions to mites ( Otodectes, Cheyletiella, Notoedres, Sarcoptes ) Infections − Bacterial pyoderma (almost always secondary) − Dermatophytosis − Feline Herpes infection (especially nose and face) − Malassezia (especially Rex and Sphinx) Less Common Ectoparasites − Feline demodecosis (The contagious short-bodied D. gatoi is commonly recognised in Europe and North America) − Lice − Infestation with Trombicula spp Immune mediated disease − Pemphigus foliaceus − Drug reactions − Sebaceous adenitis − Lymphocytic mural folliculitis Neoplasia − Epitheliotropic lymphoma − Squamous cell carcinoma (common neoplasm, uncommonly pruritic) − Feline mast cell tumours Idiopathic − Psychological pruritus − Idiopathic facial dermatitis (dirty face disease) of Persian cats (Adapted from Noli and Scarampella (2004)) Same aetiology Same protocol Same treatment Manifestations of feline allergic disease. Any one or more of the following: Milliary dermatitis Eosinophilic plaque Eosinophilic granuloma Linear plaque/granuloma Over grooming syndrome Head and neck pruritus Urticaria pigmentosa Rodent ulcer Milliary dermatitis presents as multiple small crusted papules on any part of the body.
    [Show full text]
  • Conflicts Between People and the Florida Black Bear
    JULY/AUGUST 2019 Staining Pests of Black Olive Trees | New Turf Disease UF Urban Lab, From Research PESTPRO To Products From Pest Management Education, Inc. to Landscape and Pest Managers Late-Season Defoliators On Hardwood Trees Conflicts Between People and the Florida Black Bear Port Orange, FL 32127-5801 FL Orange, Port July / August 2019 Blvd. Hill Nob 5814 Pest Management Education, Inc. | PestEducation, Pro 1 Management Pest ® TAURUSThey know a lot about flavor.SC Fipronil 9.1% Guaranteed Results That’s why it’s important to keep your menu fresh with Advion® Evolution Cockroach Gel Bait. Its enhanced bait matrix attracts even the toughest cockroaches while increasing feeding and speed of kill. Learn more about Advion Evolution and the benefits you get as part of the PestPartnersSM 365 program at SyngentaPMP.com/AdvionEvolution. 10 A new SecureChoice℠ assurance program featuring Advion Evolution is coming soon! YEAR Promise of Protection ControlSolutionsInc.com Taurus is a registered trademark of Control Solutions, Inc. Adama.com Control©2019 Syngenta. Solutions, Important: Inc. Always read and follow label instructions. Some products may not be registered for sale or use in all statesThis product or may not be registered in all states, Innovationcounties and/or you maycan haveapply. state-specificFind Us useOn requirements. Please check with your local extension service to ensure registration andplease proper check the use. CSI website for registration information. Advion Pest®, For Life ProUninterrupted™, | July PestPartners / AugustSM, SecureChoice℠,2019 the Alliance Frame, the Purpose Icon and the Syngenta logo are trademarks or service2 marks of a Syngenta Group Company. Syngenta Customer Center: 1-866-SYNGENT(A) (796-4368).
    [Show full text]
  • PRICK TESTING in INSECT BITE REACTION Dissertation Submitted
    PRICK TESTING IN INSECT BITE REACTION Dissertation submitted to The Tamil Nadu Dr. M.G.R Medical University, Chennai In fulfilment of the requirements for the award of the degree of Doctor of Medicine in Dermatology, Venereology and Leprology Under the guidance of Dr. SHANMUGA SEKAR .C, MD., Department of Dermatology, Venereology and Leprology PSG INSTITUTE OF MEDICAL SCIENCES & RESEARCH, COIMBATORE THE TAMILNADU DR. M.G.R MEDICAL UNIVERSITY, CHENNAI, TAMILNADU MAY 2018 CERTIFICATE This is to certify that the thesis entitled “PRICK TESTING IN INSECT BITE REACTION” is a bonafide work of Dr. IYSHWARIYA SIVADASAN done under the direct guidance and supervision of Dr.C.R. SRINIVAS, MD and Dr. SHANMUGA SEKAR .C, MD, in the department of Dermatology, Venereology and Leprology, PSG Institute of Medical Sciences and Research, Coimbatore in fulfillment of the regulations of The Tamil Nadu Dr.MGR Medical University for the award of MD degree in Dermatology, Venereology and Leprology. Dr. REENA RAI Dr. RAMALINGAM Professor & Head of Department DEAN Department of DVL DECLARATION I hereby declare that this dissertation entitled “PRICK TESTING IN INSECT BITE REACTION” was prepared by me under the direct guidance and supervision of Dr.C.R.SRINIVAS, MD and Dr. SHANMUGA SEKAR C., MD, PSG Institute of Medical Sciences and Research, Coimbatore. The dissertation is submitted to The Tamil Nadu Dr. MGR Medical University in fulfillment of the University regulation for the award of MD degree in Dermatology, Venereology and Leprology. This dissertation has not been submitted for the award of any other Degree or Diploma. Dr. IYSHWARIYA SIVADASAN CERTIFICATE BY THE GUIDE This is to certify that the thesis entitled “PRICK TESTING IN INSECT BITE REACTION” is a bonafide work of Dr.
    [Show full text]
  • List of Original Publications
    ARI KARPPINEN Antihistamines in the Treatment of Mosquito-Bite Allergy ACADEMIC DISSERTATION To be presented, with the permission of the Faculty of Medicine of the University of Tampere, for public discussion in the small auditorium of Building B, Medical School of the University of Tampere, Medisiinarinkatu 3, Tampere, on October 26th, 2001, at 13 o’clock. Acta Universitatis Tamperensis 841 University of Tampere Tampere 2001 ACADEMIC DISSERTATION University of Tampere, Medical School Tampere University Hospital, Department of Dermatology and Venereology Finland Supervised by Reviewed by Professor Timo Reunala Docent Antti Lauerma University of Tampere University of Helsinki Professor Ilari Paakkari University of Helsinki Distribution University of Tampere Sales Office Tel. +358 3 215 6055 P. O. B o x 617 Fax +358 3 215 7685 33014 University of Tampere [email protected] Finland http://granum.uta.fi Cover design by Juha Siro Printed dissertation Electronic dissertation Acta Universitatis Tamperensis 841 Acta Electronica Universitatis Tamperensis 136 ISBN 951-44-5190-2 ISBN 951-44-5191-0 ISSN 1455-1616 ISSN 1456-954X http://acta.uta.fi Tampereen yliopistopaino Oy Juvenes Print Tampere 2001 To my family Contents Abbreviations..................................................................................................................................................... 4 List of original publications............................................................................................................................... 5 A. INTRODUCTION
    [Show full text]
  • Eosinophilic Granuloma Complex
    Eosinophilic Granuloma Complex in Cats and Eosinophilic Granulomas in Dogs Basics OVERVIEW • Cats—“eosinophilic granuloma complex” often is a confusing term used for four distinct syndromes: (1) “eosinophilic plaque” (circumscribed, raised, round to oval lesions that frequently are ulcerated; usually located on the abdomen or thighs; lesions contain a type of white blood cell, called an eosinophil); (2) “eosinophilic granuloma” (a mass or nodular lesion containing eosinophils; usually found on the back of the thighs, on the face, or in the mouth); (3) “indolent ulcer” (circumscribed, ulcerated lesions; most frequently found on upper lip); (4) allergic miliary dermatitis (skin inflammation characterized by numerous, small, crusty bumps); the four syndromes are grouped together as “eosinophilic granuloma complex” primarily according to their clinical similarities, their frequent simultaneous development and tendency to recur, and their positive response to treatment with steroids • Dogs—”eosinophilic granulomas” are rare; not part of the eosinophilic granuloma complex; specific differences from cats are presented in the following information • “Eosinophilic” refers to eosinophils, a type of white-blood cell usually involved in allergic responses • “Granuloma” is a large inflammatory nodule or solid mass • “Complex” is a group of signs or diseases that have an identifiable characteristic that makes them similar in some fashion GENETICS • Several reports of related affected individuals and a study of disease development in a colony of cats
    [Show full text]
  • Decrease of Mosquito Salivary Gland Proteins After a Blood Meal: an Implication for Pathogenesis of Mosquito Bite Allergy
    Decrease of Mosquito Salivary Gland Proteins after a Blood Meal: An Implication for Pathogenesis of Mosquito Bite Allergy Padet Siriyasatien MD, PhD*, Kuntida Tangthongchaiwiriya MSc* Kanyarat Kraivichian MD*, Surang Nuchprayoon MD, PhD* Apiwat Tawatsin MAppl Sc**, Usavadee Thavara PhD** * Department of Parasitology, Faculty of Medicine, Chulalongkorn University ** National Institute of Health, Department of Medical Sciences, Nonthaburi SalivOlY gland protein profiles of Aedes aegypti (L) and Culex quinquefasciatus (Say) pre- and post- bloodfeeding were analyzed. SDS-PAGE studies before blood feeding of Ae. aegypti demonstrated 8 major polypeptide bands of 20, 35, 37, 42, 45, 47, 70 kDa and a high molecular weight band> 118 kDa, whereas those ofCx. quinquefasciatus demonstrated 9 major polypeptide bands of 20, 26, 36, 38, 45, 47, 49 kDa and 2 high molecular weight bands> 118 kDa. After a blood feeding, salivary gland polypeptides of Ae. aegypti at 35,37,45,47, 70 kDa and high molecular weight band> 118 kDa were depleted, while the polypeptide bands of 20, 26, 36, 38 kDa were depleted in Cx. quinquefasciatus. The presented study suggests that these major polypeptides were introduced into vertebrate hosts when a mosquito took a blood meal, Further investigation in molecular, biochemical and immunological aspects of these salivOlY gland polypeptides may provide information for better understanding in the role of these proteins in mosquito bite allergy. Keywords: Mosquito bite allergy, Aedes aegypti, Culex quinquefasciatus, Mosquito saliva!)' gland protein J Med Assoc Thai 2005; 88(Suppl 4): S255-9 Full text. e-Journal: http://www.medassocthai.orgljournal Dennal allergyto mosquitobites isa common salivary glands of several mosquito species have been problemworldwide.
    [Show full text]
  • Rupatadine for the Treatment of Allergic Rhinitis and Urticaria: a Look at the Clinical Data
    Review: Clinical Trial Outcomes For reprint orders, please contact [email protected] 4 Review: Clinical Trial Outcomes Rupatadine for the treatment of allergic rhinitis and urticaria: a look at the clinical data Clin. Invest. The second-generation antihistamine rupatadine is a new long-acting and Erminia Ridolo*,1, Marcello non-sedating drug that exerts a potent dual-antagonist activity towards the histamine Montagni1, Filippo Fassio2, H1 receptor and the PAF receptor. Rupatadine is prescribed for the relief of symptoms Ilaria Massaro3, Oliviero 4 5 of seasonal and perennial allergic rhinitis and in the treatment of chronic urticaria. Rossi , Cristoforo Incorvaia & Giorgio Walter Canonica6 Clinical trials have shown that rupatadine, which shows a rapid onset of action and 1Department of Clinical & Experimental prolonged duration of activity, is effective and well tolerated. Safety data indicate Medicine, University of Parma, Parma, Italy that rupatadine does not affect the cardiovascular system, without relevant changes 2Department of Biomedicine, Immunology in the corrected QT interval, or significantly affect psychomotor activity at the doses & Cell Therapies Unit, AOU Careggi, used in clinical practice. Here, we review the efficacy and safety profile of rupatadine University of Florence, Italy 3 in patients with allergic rhinitis and urticaria. Centre for Research, Transfer & High Education DENOTHE, University of Florence, Florence, Italy Keywords: allergic rhinitis • chronic urticaria • histamine • platelet-activating factor 4Department of Biomedicine, • rupatadine Immunoallergology Unit, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy The new antihistamine rupatadine is a potent, distinct clinical entities both respond to anti- 5Pulmonary Rehabilitation Unit, ICP orally active, non-sedating, long-acting antag- histamine treatment. This review focuses on Hospital, Milan, Italy onist of both histamine H1 receptors and PAF the clinical characteristics of rupatadine and 6Allergy & Respiratory Diseases Clinic, receptors.
    [Show full text]
  • Chronic Active EBV Infection: the Experience of the Samsung Medical Center in South Korea 11
    Bol Med Hosp Infant Mex. 2016;73(1):10---17 www.elsevier.es/bmhim CLINICAL CASE Chronic active EBV infection: the experience of the Samsung Medical Center in South Korea ∗ Tae-Hee Lee, Young-Hyeh Ko Department of Pathology, Samsung Medical Center, Sungkyunkwan University, Seoul, Korea Received 11 November 2015; accepted 3 December 2015 Available online 1 February 2016 KEYWORDS Abstract Epstein-Barr virus; Background: Chronic active EBV infection (CAEBV) of T-cell or NK-cell type is an EBV+ polyclonal, Children; oligoclonal or often monoclonal lymphoproliferative disorder (LPD) recognized as representing Chronic active the spectrum of EBV-associated T-cell and NK-cell LPD with different clinical presentations; infection; one systemic and two cutaneous disorders including hydroa vacciniforme-like T-cell LPD and NK lymphocytosis; mosquito bite hypersensitivity. The systemic form of the disease is characterized by fever, Mosquito-bite persistent hepatitis, hepatosplenomegaly and lymphadenopathy, which shows varying degrees hypersensitivity of clinical severity depending on the immune response of the host and the EBV viral load. Case reports: We described the clinicopathological findings of two children with CAEBV with a brief review of the literature. Conclusions: Recognition of the disease is important for adequate management of the patient. EBV analysis should be included in the principal diagnostic tests for febrile children. © 2015 Hospital Infantil de México Federico Gómez. Published by Masson Doyma México S.A. This is an open access
    [Show full text]
  • Systemic Epstein-Barr Virus–Positive T-Cell Lymphoma of Childhood
    CASE REPORT Systemic Epstein-Barr Virus–Positive T-cell Lymphoma of Childhood Qiong Wu, MD; Faliang Ren, MD; Dirk M. Elston, MD relapsing course, accompanied by rigors but without con- PRACTICE POINTS vulsions or cognitive changes. At times, the patient had • Systemic Epstein-Barr virus (EBV)–positive T-cell nasal congestion, nasal discharge, and cough. He also had lymphoma of childhood is a fulminant illness with a a transient eruption on the back and hands as well as an predilection for Asians and indigenous populations indurated red nodule on the left forearm. from Mexico and Central and South America. In most Before the patient was hospitalized, antibiotic therapy patients, the disease has an aggressive clinical course was administered by other physicians, but the condition of with high mortality. fever and oral ulcerscopy did not improve. After the patient was • The disease often is complicated by hemophagocytic hospitalized, new tender nodules emerged on the scalp, syndrome, coagulopathy, sepsis, and multiorgan fail- buttocks, and lower extremities. New ulcers also appeared ure. When these severe complications are absent, the on the palate. prognosis might be better. History—Two months earlier, the patient had presented • In situ hybridization for EBV-encoded RNA and for withnot a painful perioral skin ulcer that resolved after being T-cell receptor gene rearrangements is an important treated as contagious eczema. Another dermatologist tool to establish the diagnosis as well as for treatment previously had considered a diagnosis of hand-foot-and- options and predicting the prognosis. Domouth disease. The patient was born by normal spontaneous vaginal delivery, without abnormality.
    [Show full text]
  • EBV-Positive Lymphoproliferations of B- T- and NK-Cell Derivation in Non-Immunocompromised Hosts
    pathogens Review EBV-Positive Lymphoproliferations of B- T- and NK-Cell Derivation in Non-Immunocompromised Hosts Stefan D. Dojcinov 1 ID , Falko Fend 2 and Leticia Quintanilla-Martinez 2,* ID 1 Department of Cellular Pathology, University Hospital of Wales, Cardiff CF14 4XW, UK; [email protected] 2 Institute of Pathology and Neuropathology and Comprehensive Cancer Center Tübingen, University Hospital Tübingen, Eberhard-Karls-University, 72076 Tübingen, Germany; [email protected] * Correspondence: [email protected]; Tel.: +49-7071-2082979 Received: 4 February 2018; Accepted: 5 March 2018; Published: 7 March 2018 Abstract: The contribution of Epstein-Barr virus (EBV) to the development of specific types of benign lymphoproliferations and malignant lymphomas has been extensively studied since the discovery of the virus over the last 50 years. The importance and better understanding of the EBV-associated lymphoproliferative disorders (LPD) of B, T or natural killer (NK) cell type has resulted in the recognition of new entities like EBV+ mucocutaneous ulcer or the addition of chronic active EBV (CAEBV) infection in the revised 2016 World Health Organization (WHO) lymphoma classification. In this article, we review the definitions, morphology, pathogenesis, and evolving concepts of the various EBV-associated disorders including EBV+ diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS), EBV+ mucocutaneous ulcer, DLBCL associated with chronic inflammation, fibrin-associated DLBCL, lymphomatoid granulomatosis, the EBV+ T and NK-cell LPD of childhood, aggressive NK leukaemia, extranodal NK/T-cell lymphoma, nasal type, and the new provisional entity of primary EBV+ nodal T- or NK-cell lymphoma.
    [Show full text]
  • Total Ige, Mosquito Saliva Specific Ige and CD4+ Count in HIV-Infected Patients with and Without Pruritic Papular Eruptions
    Original article Total IgE, mosquito saliva specific IgE and CD4+ count in HIV-infected patients with and without pruritic papular eruptions Sukhum Jiamton,1 Taniya Kaewarpai,2 Pattama Ekapo,3 Kanokvalai Kulthanan,1 Saowalak 4 5 5 Hunnangkul, John J. Boitano and Sirichit Wongkamchai Summary significantly higher than for those without PPE. A comparison of the mean arbitrary scores of the Background: Pruritic Papular Eruption (PPE) is specific IgE in HIV patients, with and without a skin disorders found in HIV infected patients. PPE, was non-significant (p = 0.152). However, However, the exact etiology of PPE is not 44% (11/25) of the HIV patients with PPE had an documented. It has been suggested that PPE arbitrary score above the mean score of mosquito might result from arthropod bites. bite allergic subjects, as compared to only 3.3% Objective: The aim of this study was to (2/60) of HIV patients without PPE. investigate those factors in the HIV patient Conclusions: It may be concluded that the contributing to the occurrence of PPE, including etiology of PPE in the HIV patient may be specific IgE against mosquito saliva allergens, heterogeneous or multi-causal with allergic total IgE, CD4 cell counts and their associations. responses to the mosquito saliva allergen being Methods: Specific IgE against saliva allergens of only partially responsible. (Asian Pac J Allergy Cx. quinquefasciatus mosquito was measured in Immunol 2014;32:53-9) 25 HIV patients with PPE and in 60 HIV without Key words: pruritic papular eruptions, HIV, PPE by a time-resolved fluorescence immunoassay mosquito saliva allergens, specific IgE, total IgE (TRIFA).
    [Show full text]
  • June 2016 Newsletter
    To the Greatest Father of all, Happy Father’s Day to our Heavenly Father! THE FRIENDLY CONNECTION NEWSLETTER FRIENDLY TEMPLE CHURCH OF GOD IN CHRIST “W HERE EVERYBODY IS SOMEBODY AND JESUS CHRIST IS LORD !” 16570 “E” STREET VICTORVILLE, CA 92395 -- (760) 245-8788 DR. ROGER THOMAS, PASTOR - DR. MARIE THOMAS, FIRST LADY June 2016 TURN BACK TO GOD IN 2016 Volume 7, Issue 6 and wait patiently on Him, for He is the author and finisher of our faith. Hebrews 12:1-2 Published Monthly ================================================================================================================================================================================================================================================ ================= “… let us lay aside every weight, and the sin which doeth easily Newsletter Staff: beset us, and run with patience the race that is set before us.” EDITOR-IN-CHIEF FROM THE PASTOR’S DESK Deborah “A DOLLAR’S WORTH JUST WON’T DO” continued Thompson-Ealy EPHESIANS 5:18 ASSOCIATE EDITOR: “And be not drunk with wine, wherein is excess; Evangelist Henrietta but be filled with the Spirit…” Givens We are in church to become spiritually stronger so that we can STAFF MEMBERS: help somebody else get saved and become stronger in the Lord. If Elder Larry Ealy you have been saved for many years and no one else in your family Bettie Young is saved, it’s time to question your salvation, or the kind of life you Sherease Durden have been living before your family and before God. Mary Jackson Many people in the church have lost their JOY in the Lord because COLUMNISTS: all they wanted was “a dollar’s worth”. Remember, if you don’t Charmayne Moore put anything in to worship, you won’t get anything out of it.
    [Show full text]